Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-10-17

Clinical Trial Update: A Study of Isatuximab-based Therapy in Participants With Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of isatuximab-based therapy for lymphoma was terminated, with results posted in October 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SARCLISA (isatuximab)

Snippet

Sponsor: Sanofi | Conditions: Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-10-17